
Schematic illustration of the new MOF Antibody crystals and their ability to specifically seek out cancer cells to detect them and deliver highly potent drugs with unprecedented precision.
CREDIT: Dr Francesco Carraro and Prof Paolo Falcaro (Co-First and Co-Senior author on the Advanced Materials Paper)
It sounds like the stuff of science fiction: a man-made crystal that can be attached to antibodies and then supercharge them with potent drugs or imaging agents that can seek out diseased cells with the highest precision, resulting in fewer adverse effects for the patient.
However, that is precisely what researchers from the Australian Centre for Blood Diseases at Monash University in collaboration with the TU Graz (Austria) have developed: the world’s first metal-organic framework (MOFs) antibody-drug delivery system that has the potential to fast-track potent new therapies for cancer, cardiovascular and autoimmune diseases.
The in vitro study showed that when MOF antibody crystals bind to their target cancer cells and if exposed to the low pH in the cells, they break down, delivering the drugs directly and solely to the desired area.
The metal-organic framework, a mixture of metal (zinc) and carbonate ions, and a small organic molecule (an imidazole, a colourless solid compound that is soluble in water) not only keeps the payload attached to the antibody but can also acts as a reservoir of personalised therapeutics. This is a benefit with the potential to become a new medical tool to target specific diseases with customised drugs and optimised doses.
The findings are now published in the world-leading journal Advanced Materials.
Co-senior author Professor Christoph Hagemeyer, Head of the NanoBiotechnology Laboratory at the Australian Centre for Blood Diseases, Monash University, says while more funding is needed to take the research into the next phase and to patients, the new method is cheaper, faster and more versatile than anything available currently.
“The method offers the opportunity to personalise treatment and given the precision possible, may eventually change the current dosage needed for patients, resulting in fewer side effects and making treatments cheaper,” said Professor Hagemeyer.
Co-first author Dr Karen Alt, Head of the Nano Theranostics Laboratory at the Australian Centre for Blood Diseases, Monash University, says: “With just 0.01 per cent of chemotherapy currently reaching the cancer tissue, this revolutionary new method can boost the potency of the drugs reaching their target.”
“With over 80 different monoclonal antibodies approved for clinical use, this approach has enormous potential to improve these antibodies for the targeted delivery of diagnostic agents and therapeutic drugs. The goal is that ultimately the clinical translation of this technology will improve the quality of life for patients suffering from serious diseases,” said Dr Alt.
Original Article: Researchers develop a world-first antibody-drug delivery system
More from: Monash University | Graz University of Technology
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Antibody-drug delivery system
- Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
Denali is advancing OTV:MAPT, targeting tau for Alzheimer’s disease, and OTV:SNCA, targeting alpha-synuclein for Parkinson’s disease, in the investigational new drug (IND)-enabling stage of ...
- OS Therapies’ (OSTX) IPO: A High-Stakes Debut Amid Promising Cancer Treatment Breakthroughs
On July 24, 2024, OS Therapies announced promising data from its Phase 1 clinical trial of OST-HER2, an immunotherapy targeting HER2-expressing solid tumors. The trial results were positive for ...
- BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma
Primary endpoint met in a Phase 2 trial evaluating the investigational mRNA immunotherapy BNT111 in combination with the PD-1 checkpoint ...
- Alzheimer’s: drug delivery and the blood brain barrier conundrum
The blood-brain barrier is the biggest hurdle in treating brain diseases, and research on overcoming this challenge is ongoing.
- Clarifying a synergistic effect between different types of antibodies in cancer treatment
In many types of cancer, tumor cells have an overabundance of specific membrane proteins; this often grants them special properties, such as accelerated growth, immune system avoidance ... this ...
Go deeper with Google Headlines on:
Antibody-drug delivery system
[google_news title=”” keyword=”antibody-drug delivery system” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Metal-organic framework antibody-drug delivery
- Best Metal Credit Cards Of July 2024
Commissions do not affect our editors' opinions or evaluations. There’s something satisfying about the heft and feel of a metal credit card. Whether it’s the cachet that comes with owning one ...
- New and improved drug-delivery molecules for skeletal muscle
Researchers from Tokyo Metropolitan University have created a new drug-delivery molecule, a zwitterionic polymer complex that can help get plasmid DNA inside cells when injected into skeletal muscle, ...
- Organic Chemistry News
July 30, 2024 — Scientists have revealed that injury dressings found in first-aid kits can reliably be used to identify shark species involved in bite incidents by deploying medical gauze to ...
- Entering the recognition domain
The host–guest properties of metal–organic frameworks have usually relied ... catalysis and biological applications, including drug delivery 7. As beautifully demonstrated by Li, Zhang and ...
- Antibody-drug conjugate
Sotio Biotech AS and Biocytogen Pharmaceuticals Co. Ltd. are partnering to discover antibody-drug conjugates (ADCs) via an option and license agreement worth up to $325.5 million plus sales royalties.
Go deeper with Google Headlines on:
Metal-organic framework antibody-drug delivery
[google_news title=”” keyword=”metal-organic framework antibody-drug delivery” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]